Prostate Cancer Trial, Recruiting NCT06037954 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06037954
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • People who have been diagnosed with breast, colorectal, lung, or prostate cancer at age 65 or older, based on medical records or their own report
  • People who are currently receiving cancer treatment (such as radiation, chemotherapy, immunotherapy, or surgery) or who finished treatment within the last six months
  • People who score 5 or higher on a standard depression screening questionnaire called the PHQ-9
  • People who speak and understand English well, as confirmed by a brief language check with a research team member

For healthcare providers:

  • People who work in oncology, nursing, social work, psychology, or psychiatry
  • People who spend at least half of their working time in oncology
  • People who have been providing cancer care for at least three years at the time of joining the study
  • People who are fluent in English

Who may not be able to join:

For patients:

  • People with severe memory or thinking difficulties, as measured by a standard cognitive test (the Blessed Orientation Memory Concentration test)
  • People whom research staff judge to be too unwell or physically weak to take part in the study procedures
  • People who are receiving hospice care at the time of enrollment
  • People who are currently receiving mental health treatment

For healthcare providers:

  • No specific exclusion criteria have been listed for providers

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kelly McConnell, PhD, Memorial Sloan Kettering Cancer Center

Phone: 646-888-0026

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 September 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Refusal rates; Attrition rates

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov